We are leading efforts to address new challenges in translational medical research—but we can’t do it alone.
Through robust and meaningful collaboration, we bring our novel platforms directly to those who need it most, with coordinated care by notable experts in the field.
For more information or inquiries on collaborations and partnerships, please contact partnering@ovidrx.com.
Ovid currently has several ongoing corporate partnerships:
Angelini Pharma
In July 2020, Ovid and Angelini Pharma, an Italian family-owned pharmaceutical company committed to helping patients with a constant and prevalent focus on mental health, rare diseases, and consumer health, entered into an exclusive license agreement to develop, manufacture, and commercialize OV101 (gaboxadol) for the potential treatment of Angelman syndrome. OV101 is a delta (δ)-selective GABAA receptor agonist. Under the terms of the agreement, Angelini Pharma obtained exclusive development, manufacturing, and commercialization rights to OV101 in the European Union and other countries in the European Economic Area, and also Switzerland, Turkey, the United Kingdom, and Russia.
Read Ovid press release »
Read Angelini press release »
Takeda
In January 2017, Takeda and Ovid began an innovative clinical development and commercialization collaboration partnership to develop OV935/TAK-935 (soticlestat), a highly selective first-in-class CH24H inhibitor with the potential to reduce seizure susceptibility and improve seizure control in rare developmental and epileptic encephalopathies (DEE). As part of this agreement, Ovid leads clinical development activities and commercialization in the United States, Europe, Canada and Israel. Takeda will lead commercialization in Japan, and has the option to lead in Asia and other selected geographies.
Read Ovid press release »
Read Takeda press release »
Lundbeck
In March 2015, Ovid entered into an exclusive worldwide license agreement for OV101 (gaboxadol) with Lundbeck, a global pharmaceutical company specialized in brain diseases. OV101, a highly selective GABAA receptor (GABAAR) agonist, has been tested in clinical trials and holds the potential to be the first oral medication to treat patients with Angelman syndrome and Fragile X syndrome. Under the terms of the agreement, Ovid obtained exclusive worldwide development and commercialization rights for OV101 and is responsible for all future development and commercialization for OV101.
Ovid currently has several ongoing research partnerships:
University of Connecticut
In July 2020, Ovid entered a strategic research collaboration and license agreement with the University of Connecticut School of Medicine (“UConn”) to accelerate the development of a next-generation short hairpin RNA (shRNA)-based therapeutic for Angelman syndrome. An shRNA-based therapeutic may address the most common cause of Angelman syndrome, the loss of function of the gene that codes for ubiquitin protein ligase E3A (UBE3A), by reducing the expression of UBE3A antisense, potentially restoring the function of UBE3A. Under the terms of the research collaboration, Ovid is working closely with UConn and gained exclusive access to identified genetic sequences for a potential shRNA-based therapeutic.
Columbia University
In June 2020, Ovid and Columbia University Irving Medical Center (“Columbia”) began a strategic research collaboration to advance genetic-based therapies for a range of rare neurological conditions, complementary of Ovid’s pipeline. This collaboration provided Ovid with the potential to expand its future drug development portfolio and impact individuals living with rare genetic neurological conditions by working closely with the Precision Medicine Resource at the Irving Institute at Columbia. Under this research and translational development alliance, Columbia will align its expertise in rare disease genetics and deep clinical understanding of rare neurological diseases with Ovid’s discovery, translational, and clinical development expertise in neurodevelopmental disorders and rare epilepsies.
Northwestern University
In December 2016, Ovid entered into a license agreement with Northwestern University that granted Ovid an exclusive, worldwide license to research, develop, manufacture, and commercialize OV329. Ovid is exploring the potential benefits of OV329 in a number of treatment-resistant epilepsies, including for seizures associated with Tuberous Sclerosis Complex and Infantile Spasms.
